Reduced intraocular pressure (IOP) in adult patients with open-angle glaucoma or ophthalmic hypertension who do not respond sufficiently to topical monotherapy with beta-blockers or prostaglandin analogues and require combination therapy and are shown to use non-eyed eye drops.
Composition and form of release
The main active ingredients: timolol, tafluprost.
Excipients: glycerin, sodium hydrogen phosphate, disodium edetate, polysorbate, sodium hydroxide and / or concentrated hydrochloric acid, water for injections.
It is issued in the form of drops for eyes, arrives in drugstore sale in tubes-droppers (for single use) in volume on 0,3 ml in each of which contains:
- 1.5 mg timolol;
- 4.5 mcg tafluprost.
This ophthalmic drug belongs to the combined antiglaucoma drugs.
One of the active ingredients is timolol, a non-selective beta-blocker.
Its use leads to a decrease in both elevated and normal intraocular pressure due to the mechanism of action, which is associated with the ability to reduce the release (secretion) of watery moisture and improve its outflow from the eyes.
Has the ability to inhibit beta-receptors (β1), which are localized mainly in the heart muscle. As a result, the heart rate decreases, and then the minute volume of the myocardium.
The use of this drug also causes an increase in the sensitivity of the upper and lower respiratory tract.
Tafluprost is a fluorinated prostaglandin F2 analogue. Pharmacodynamic studies have shown that this substance (tafluprost) also has the ability to reduce intraocular pressure.
This ophthalmic solution is used if the “first line” drugs for treatment do not work:
- increased intraocular pressure (glaucoma, or ophthalmic hypertension);
- glaucoma (chronic open-angle glaucoma);
- glaucoma, which is a consequence of lens removal (glaucoma in aphakia).
This drug is not used if the patient has (or has ever experienced) a hypersensitivity reaction (allergy) to the use of timolol or one of the other components of the drug.
It is also contraindicated to use at:
- bronchial hyperreactivity, bronchial asthma, including in the anamnesis;
- chronic obstructive airways disease;
- sinus bradycardia;
- sinus node weakness syndrome, including sinoauricular block;
- atrioventricular block of the II or III degree which is not controlled by a pacemaker;
- severe heart failure;
- high degree of atrioventricular block;
- congestive heart failure;
- cardiogenic shock, diabetes mellitus, hypoglycemia caused by it.
Caution should be exercised when prescribing to patients with severe peripheral circulatory disorders (particularly Raynaud’s syndrome).
Use during pregnancy and breastfeeding
Treatment of pregnant women is highly undesirable, only for serious indications.
Breastfeeding should be discontinued during treatment.
Method of application and dose
These drops are intended only for instillation into the conjunctiva of the eye. After instillation, it is desirable to cover the eyelids so that the drug is better absorbed.
The optimal dosage is 1 drop once a day, at night. One tube is enough for 1 instillation of two eyes in the specified dosage – 1 drop per 1 eye.
It is not recommended to increase the dosage.
Can be used for a long time.
The patient should remember that glaucoma requires regular monitoring of intraocular pressure.
Patients with highly pigmented irises should be aware that their blood pressure reduction will be less effective.
An overdose of this drug usually does not cause special side effects due to low toxicity.
In rare cases, at long considerable excess of a dosage were observed:
- lowering blood pressure;
- congestive heart failure, cardiogenic shock;
- bradycardia, cardiac arrest;
- respiratory disorders, in particular bronchospasm;
- gastrointestinal disorders;
- confusion of consciousness;
In case of overdose, atropine, glucagon, diazepam, beta-sympathomimetics are recommended. The use of pacemakers is recommended.
Usually the drug is absorbed into the systemic bloodstream, it can cause the following side effects in the form of:
- angioneurotic edema, allergic urticaria, rash, pruritus, anaphylactic reactions, facial edema, redness;
- hypoglycemia, hyperglycemia, diabetes;
- insomnia, depression, nightmares, memory loss;
- syncope, cerebrovascular disorders, cerebral ischemia, myasthenia gravis, dizziness, paresthesias and headaches, migraines;
- visual disturbances, changes in refraction, itching, tingling, tearing, redness, blepharitis, keratitis, pain, conjunctivitis, photophobia, dry eyes, scaling on the eyelids, uveitis, eyelid eczema, corneal pigmentation, diplopia, corneal erosion;
- bradycardia, angina, tachycardia, edema, heart failure, myocardial infarction, cardiac arrest;
- hypotension, stroke, tinnitus, Raynaud’s syndrome;
- asthma, bronchitis, bronchospasm, shortness of breath, cough, rhinitis, COPD;
- nausea, dyspepsia, diarrhea, dry mouth, abdominal pain, vomiting;
- alopecia, psoriasis, rash, systemic lupus erythematosus;
- myalgia, arthropathy, arthralgia;
- sexual dysfunction, decreased libido;
- asthenia, fatigue, dermatitis, drowsiness, difficulty urinating;
- corneal calcification (rare).
Conditions and terms of storage
This drug is able to retain its medicinal properties for 3 years from the date of manufacture indicated on the package.
The drug should be kept out of reach of children. Storage temperature – from 2 to 8 ° C.
After opening the foil bag, the drug retains its properties for 4 weeks, provided it is stored at a temperature not exceeding 25 ° C.